Another JAK inhibitor -- ruxolitinib -- is already approved as a topical formulation (Opzelura) to treat vitiligo. But the indication is only for vitiligo affecting the face and no more than 10% ...

Lisa: I follow a vitiligo management plan developed with my dermatologist where I use Opzelura ® (ruxolitinib) cream 1.5%. I first noticed some repigmentation, particularly on my face ...

Opzelura is a treatment for nonsegmental vitiligo in patients 12 and older, making it the first and only cream in the U.S.

It is not known if OPZELURA is safe and effective in children less than 12 years of age with nonsegmental vitiligo. Serious Infections: OPZELURA contains ruxolitinib. Ruxolitinib belongs to a ...

Incyte has made further progress with its ruxolitinib cream, notching up a phase 3 trial showing it can re-pigment skin in vitiligo ahead of a key FDA decision in atopic dermatitis.

Now, all eyes are set on the FDA-approved drug Ruxolitinib, manufactured by Incyte Pharmaceuticals, which is the first drug that can restore pigment in patients with nonsegmental vitiligo.

Vitiligo on the penis occurs when patches ... pimecrolimus, and Opzelura (ruxolitinib) which affect your body's immune response. You should only use a topical medication on your penis if your ...

Last year, Incyte became the first pharma company to get approval for a drug that can re-pigment the skin in vitiligo – topical JAK1/JAK2 inhibitor Opzelura (ruxolitinib) – for patients whose ...

A notable shift in progress occurred in 2022, with the Food and Drug Administration approval of the topical Janus kinase (JAK) inhibitor ruxolitinib 1.5% for patients with nonsegmental vitiligo ...

Incyte’s ruxolitinib franchise, made up of blockbuster JAK inhibitor Jakafi and its topical counterpart Opzelura, have been ...

In 2022, the FDA approved the first re-pigmentation therapy for vitiligo: Opzelura (ruxolitinib) cream. Clinical trials found that only 30% of patients using the cream regained 75% or more skin re ...

Incyte Reports 2024 Fourth Quarter and Year-End Financial Results, Provides 2025 Financial Guidance and Highlights 2025 R&D ...